Dr. Paul SongVice President Business Development Team
Dr. Paul H. Song, currently Vice President in Business Development Team at Samsung Bioepis, has 23yrs of biologics drug discovery/development experiences for both innovative biologics and biosimilar drugs targeting immunology and oncology indications. During 2015~2016, Paul was the head of Cell Engineering/Next Generation Product team, and was responsible for generating production cell lines for the 2nd wave biosimilar projects and developing technologies to support next-generation production platforms. Between 2010~2014, Paul led the Biotherapeutics Lab at Samsung Advanced Institute of Technology (SAIT), a central research center within the Samsung group. He was responsible for building antibody research and development capabilities from early target discovery, lead generation and clinical candidate selection, while in parallel, internalizing key platform technologies to support biologics R&D. His effort led to generation of two novel, potential best-in-class antibodies for oncology indication. Before Samsung, Paul spent 14yrs in BioTDR at Lilly Research Laboratories in US as a senior scientist/principle research scientist, where he gained in-depth biotherapeutics drug discovery and development experiences for autoimmune and oncology indications. Paul did his post-doctoral research at Tularik Inc (currently Amgen) where his research focused on identification of key signaling mediators for the TNF signal transduction pathway, and contributed to discovery and characterization of IKK beta, a critical mediator of NF-kB signaling.